Open PositionsBack to Open Positions
Associate Computational Biologist
You are an innovative, collaborative and enthusiastic associate computational biologist who is interested in working on a variety of multimodal bioinformatics projects centered on oncology target identification, drug discovery and translational research. You will help derive new biological insights by applying novel machine learning and statistical methods to internal and external datasets, including next generation sequencing data, genome-wide CRISPR screens, and proteomic data. As an associate computational biologist at Cedilla, you will develop novel methods, analysis strategies and tools to filter, distill, and visualize multi-dimensional datasets to generate focused hypotheses to drive primary research working collaboratively with multi-disciplinary teams and external collaborators.
About You and How You Will Have an Impact
We view you as a critical thought leader in the company and you will contribute in countless ways.
A few of them are:
- Develop and apply algorithms to omics and functional genomic datasets, analyze data quality, critically review and analyze results, communicate results to biologists and computational biologists.
- Develop innovative, robust, analysis pipelines for pooled, genome-wide CRISPR screen datasets and large-scale proteomic datasets
- Explore and develop novel data visualization tools
- Collaborate with lab scientists as a project team member
Some of the highlights of your background are:
- A Bachelor’s degree in a quantitative discipline (such as computer science, bioinformatics, engineering, or physics), or in biology with a strong quantitative background
- Fast learner, innovative and analytical thinker, creative and a team-player
- Background in statistics and machine learning is preferred
- Knowledge of cancer biology is a plus
- Proficient programming skills and computational analysis background. Experience with R, Python, and SQL are desirable
You are not just an amazing scientist, you’re the whole package!
Cedilla is leveraging a growing understanding of the principles that dictate protein stability and applying those principles to target proteins that drive cancer and other diseases. Cedilla’s integrated product engine includes target-centric and unbiased approaches and is designed to produce small molecule therapeutics that degrade protein targets. Although degradation by small molecules has been observed serendipitously, degradation as a mechanism of action has not been pursued systematically in small molecule drug discovery.
We were launched in April 2018 and are backed by Third Rock Ventures